BACE inhibitor

This page shows the latest BACE inhibitor news and features for those working in and with pharma, biotech and healthcare.

Merck BACE inhibitor adds to litany of Alzheimer's trial failures

Merck BACE inhibitor adds to litany of Alzheimer's trial failures. Interim data shows “ virtually no chance” of clinical success for verubecestat. ... The latest disappointment comes from a phase II/III study of Merck &Co's BACE inhibitor verubecestat

Latest news

Biogen rises on more positive data for Alzheimer's candidate

compounds. Last week, it partnered with AstraZeneca (AZ) on MEDI1814, an antibody against amyloid-beta 42 (Aβ42) in phase I trials, and is also working with AZ on BACE inhibitor AZD3293,
Lilly taps AstraZeneca for another anti-amyloid drug

The two companies are already working together on AZD3293, a BACE inhibitor which is designed to interrupt the formation of Aβ at an early stage in the process, and are running ... secretase inhibitor semagacestat.
Lilly sinks as solanezumab fails again in Alzheimer's

trial in 'prodromal' patient's in the earliest stages of the disease due to report results in 2021 – as well as other pipeline projects such as its AstraZeneca-partnered BACE inhibitor ... Antibodies that directly target amyloid, small-molecule BACE
AZ-Lilly start second pivotal trial of fast-tracked Alzheimer's drug

The amyloid-targeting BACE inhibitor drug has started a second late-stage trial and - if successful - could be the first treatment for Alzheimer's that targets an underlying mechanism in the ... the BACE inhibitor to placebo over a three-year period,
Eisai and Biogen plan phase III trials for Alzheimer's drug

Eisai and Biogen plan phase III trials for Alzheimer's drug. BACE inhibitor E2609 may offer new treatment option. ... Eisai and Biogen have opted to take their BACE inhibitor E2609 into phase III trials, raising hopes of a new treatment option for

More from news
Approximately 2 fully matching, plus 22 partially matching documents found.

Latest Intelligence

Deal Watch table for September 2014

Licence and collaboration. Oral BACE inhibitor in phase I for Alzheimer's disease. ... TGR-1202 an oral P13K-delta inhibitor in phase II for haematological malignancies.
Pharma deals during September 2014

The product, an oral PK13 delta inhibitor appears to have completed phase 2 the stage when most options would expire. ... AstraZeneca and Lilly have announced a joint development and commercialisation deal for AstraZeneca's BACE inhibitor in phase I for
Eisai: Bucking the trend with R&D growth

BACE inhibitor E2609.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Senior Programme Executive: Salary TBC

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Senior Account Manager / Account Director: Great salary and bebefits

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Editorial Director – Medical Education – Oxford: Negotiable

Senior Account Manager – Med Comms – Kent: Salary TBC

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Account Manager – Med Comms – London: Salary TBC

Medical Writer - (London, Brighton or Copenhagen): Competitive

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Scientific Director: Great salary and bebefits

Senior Medical Writer: Great salary and bebefits

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

Senior Account Manager or AD - Medical Communications: Salary TBC

Senior Medical Writer: Great salary and benefits

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Editor – Medical Education Agency – Bucks: Salary TBC

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

Subscribe to our email news alerts

PMHub

Add my company

Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement: Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies: Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...